Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-30 23:19:18 - browse：131

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

WSS

Pharma patents targeted by Biden in move to slash drug prices

Pregnancy discrimination could be enabled by AI

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

First Opinion Podcast: How to protect health care in times of war

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Pfizer plans to depart BIO

Wikipedia

Wikipedia

hotspot

Activists slam private health insurers over coverage restrictions

Telehealth options flood the market as retailers push virtual care

As demand for Covid shots wanes, Moderna seeks its next success

Cassava reveals details — and problems — with Alzheimer's study

New air purifier tech could be key to improving indoor air quality

Diversifying clinical trials isn't enough to close racial gaps: study

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Medicare details structure of new drug price negotiation program

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

explore

FDA has safety concerns on CRISPR

Medtronic CEO on promising devices for diabetes, hypertension

Biden's order seeks to regulate AI risk without stifling innovation

CMS should re

Leukemia patients are helped by Syndax's new type of therapy

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

knowledge

focus

hotspot

hotspot